Gilead shows deal appetite, taking out ‘don’t eat me’ play Forty Seven for $4.9B

After adding an asset in a potentially registrational trial, Gilead management says more deals could follow

If Gilead’s takeout of Forty Seven isn’t the transformative oncology deal some have expected under Chairman and CEO Daniel O’Day, the $4.9 billion acquisition does give the company a clinical candidate that has already begun a potentially pivotal study in myelodysplastic syndromes.

On a conference call Monday, Gilead Sciences Inc. (NASDAQ:GILD) management said the deal is squarely in line with its strategy of seeking small-to-medium-sized bolt-on acquisitions, as well

Read the full 684 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers